Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation.
This article was originally published by CancerNetwork®.
The FDA has approved ivosidenib (Tibsovo) for patients with relapsed/refractory myelodysplastic syndrome (MDS) with an IDH1 mutation detected by an FDA-approved test, according to a press release from the agency.1
In conjunction with ivosidenib’s approval, the FDA also approved the Abbott RealTime IDH1 Assay as a companion diagnostic for this patient population.
A total of 18 patients were evaluated in an open-label, single-arm, multicenter phase 1 trial (NCT02074839). A total of 39% of patients had a complete or partial remission. The median duration of complete remission was between 1.9 and 80.8 months.
Patients had a median time to complete remission of 1.9 months. There were 9 patients who required transfusion due to MDS at the beginning of the study, and 6 no longer needed a transfusion after treatment with ivosidenib.
“Today’s approval represents an important treatment advancement for rare blood cancers, and more specifically, patients with relapsed or refractory MDS who have an IDH1 mutation,” said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research.
The most common adverse effects (AEs) included diarrhea, constipation, nausea, joint pain, fatigue, cough, muscle ache, or rash. However, it was noted that these were seen in patients with acute myeloid leukemia (AML), of which, this indication was originally approved.2 QTc prolongation was also observed.
The boxed warning includes the AE of differentiation syndrome, which may be fatal if it’s not treated. When symptoms are first reported, corticosteroids should be used, and patients must be monitored closely until the resolution of symptoms.
In May 2022, ivosidenib plus azacitidine was approved for patients with newly diagnosed AML for those who were susceptible to IDH1 mutation as detected by an FDA-approved test for patients who are 75 years or older.2 The regimen was also indicated for patients who have comorbidities that prevent the use of intensive induction chemotherapy.
“Through the FDA’s Oncology Center of Excellence Rare Cancers Program, we remain committed to promoting scientific innovation and advancing the development of safe and effective novel therapies to treat patients with rare cancers,” Pazdur concluded.
References
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More